PMC:7408073 / 98305-98738 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T512","span":{"begin":141,"end":146},"obj":"Body_part"},{"id":"T513","span":{"begin":290,"end":298},"obj":"Body_part"}],"attributes":[{"id":"A512","pred":"fma_id","subj":"T512","obj":"http://purl.org/sig/ont/fma/fma68877"},{"id":"A513","pred":"fma_id","subj":"T513","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"It has been shown to bind/inhibit ACE2 enzymatic activity even at low/acidic pH (pH 6.5, [115]) typical of hypercapnia (as it might occur in lungs of COVID-19 patients) when human ACE2 activity is maximal [79]; nevertheless, it retains its inhibitory effects on soluble ACE2 bound to spike proteins [24], indicating that it is able to bind and inhibit ACE2 activity regardless ACE2 binding to SARS-CoV-2 particles or to S1 fragments."}

{"project":"LitCovid-PubTator","denotations":[{"id":"3437","span":{"begin":34,"end":38},"obj":"Gene"},{"id":"3438","span":{"begin":180,"end":184},"obj":"Gene"},{"id":"3439","span":{"begin":270,"end":274},"obj":"Gene"},{"id":"3440","span":{"begin":352,"end":356},"obj":"Gene"},{"id":"3441","span":{"begin":377,"end":381},"obj":"Gene"},{"id":"3442","span":{"begin":284,"end":289},"obj":"Gene"},{"id":"3443","span":{"begin":159,"end":167},"obj":"Species"},{"id":"3444","span":{"begin":174,"end":179},"obj":"Species"},{"id":"3445","span":{"begin":393,"end":403},"obj":"Species"},{"id":"3446","span":{"begin":107,"end":118},"obj":"Disease"},{"id":"3447","span":{"begin":150,"end":158},"obj":"Disease"}],"attributes":[{"id":"A3437","pred":"tao:has_database_id","subj":"3437","obj":"Gene:59272"},{"id":"A3438","pred":"tao:has_database_id","subj":"3438","obj":"Gene:59272"},{"id":"A3439","pred":"tao:has_database_id","subj":"3439","obj":"Gene:59272"},{"id":"A3440","pred":"tao:has_database_id","subj":"3440","obj":"Gene:59272"},{"id":"A3441","pred":"tao:has_database_id","subj":"3441","obj":"Gene:59272"},{"id":"A3442","pred":"tao:has_database_id","subj":"3442","obj":"Gene:43740568"},{"id":"A3443","pred":"tao:has_database_id","subj":"3443","obj":"Tax:9606"},{"id":"A3444","pred":"tao:has_database_id","subj":"3444","obj":"Tax:9606"},{"id":"A3445","pred":"tao:has_database_id","subj":"3445","obj":"Tax:2697049"},{"id":"A3446","pred":"tao:has_database_id","subj":"3446","obj":"MESH:D006935"},{"id":"A3447","pred":"tao:has_database_id","subj":"3447","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"It has been shown to bind/inhibit ACE2 enzymatic activity even at low/acidic pH (pH 6.5, [115]) typical of hypercapnia (as it might occur in lungs of COVID-19 patients) when human ACE2 activity is maximal [79]; nevertheless, it retains its inhibitory effects on soluble ACE2 bound to spike proteins [24], indicating that it is able to bind and inhibit ACE2 activity regardless ACE2 binding to SARS-CoV-2 particles or to S1 fragments."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T549","span":{"begin":150,"end":158},"obj":"Disease"},{"id":"T550","span":{"begin":393,"end":401},"obj":"Disease"},{"id":"T551","span":{"begin":393,"end":397},"obj":"Disease"}],"attributes":[{"id":"A549","pred":"mondo_id","subj":"T549","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A550","pred":"mondo_id","subj":"T550","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A551","pred":"mondo_id","subj":"T551","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"It has been shown to bind/inhibit ACE2 enzymatic activity even at low/acidic pH (pH 6.5, [115]) typical of hypercapnia (as it might occur in lungs of COVID-19 patients) when human ACE2 activity is maximal [79]; nevertheless, it retains its inhibitory effects on soluble ACE2 bound to spike proteins [24], indicating that it is able to bind and inhibit ACE2 activity regardless ACE2 binding to SARS-CoV-2 particles or to S1 fragments."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1200","span":{"begin":3,"end":6},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T1201","span":{"begin":49,"end":57},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T1202","span":{"begin":141,"end":146},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T1203","span":{"begin":174,"end":179},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T1204","span":{"begin":185,"end":193},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T1205","span":{"begin":357,"end":365},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T1206","span":{"begin":420,"end":422},"obj":"http://purl.obolibrary.org/obo/CLO_0050050"}],"text":"It has been shown to bind/inhibit ACE2 enzymatic activity even at low/acidic pH (pH 6.5, [115]) typical of hypercapnia (as it might occur in lungs of COVID-19 patients) when human ACE2 activity is maximal [79]; nevertheless, it retains its inhibitory effects on soluble ACE2 bound to spike proteins [24], indicating that it is able to bind and inhibit ACE2 activity regardless ACE2 binding to SARS-CoV-2 particles or to S1 fragments."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T449","span":{"begin":290,"end":298},"obj":"Chemical"}],"attributes":[{"id":"A94230","pred":"chebi_id","subj":"T449","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"It has been shown to bind/inhibit ACE2 enzymatic activity even at low/acidic pH (pH 6.5, [115]) typical of hypercapnia (as it might occur in lungs of COVID-19 patients) when human ACE2 activity is maximal [79]; nevertheless, it retains its inhibitory effects on soluble ACE2 bound to spike proteins [24], indicating that it is able to bind and inhibit ACE2 activity regardless ACE2 binding to SARS-CoV-2 particles or to S1 fragments."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T161","span":{"begin":107,"end":118},"obj":"Phenotype"}],"attributes":[{"id":"A161","pred":"hp_id","subj":"T161","obj":"http://purl.obolibrary.org/obo/HP_0012416"}],"text":"It has been shown to bind/inhibit ACE2 enzymatic activity even at low/acidic pH (pH 6.5, [115]) typical of hypercapnia (as it might occur in lungs of COVID-19 patients) when human ACE2 activity is maximal [79]; nevertheless, it retains its inhibitory effects on soluble ACE2 bound to spike proteins [24], indicating that it is able to bind and inhibit ACE2 activity regardless ACE2 binding to SARS-CoV-2 particles or to S1 fragments."}

{"project":"2_test","denotations":[{"id":"32708755-22777933-20679022","span":{"begin":90,"end":93},"obj":"22777933"},{"id":"32708755-15791205-20679023","span":{"begin":300,"end":302},"obj":"15791205"}],"text":"It has been shown to bind/inhibit ACE2 enzymatic activity even at low/acidic pH (pH 6.5, [115]) typical of hypercapnia (as it might occur in lungs of COVID-19 patients) when human ACE2 activity is maximal [79]; nevertheless, it retains its inhibitory effects on soluble ACE2 bound to spike proteins [24], indicating that it is able to bind and inhibit ACE2 activity regardless ACE2 binding to SARS-CoV-2 particles or to S1 fragments."}